3 results
Approved WMOCompleted
To demonstrate that oral apixaban 2.5 mg BID is superior to subcutaneous (SC)enoxaparin 40 mg QD in reducing the event rate on the composite endpoint of adjudicated asymptomatic and symptomatic DVT, non-fatal PE and all-cause death through Day 12 of…
Approved WMOCompleted
First objective: To assess improvement in live birth rate after levothyroxine supplementation. Secondary objective: 1) to test the hypothesis that levothyroxine lowers the risk for miscarriage and preterm birth 2) to test the hypothesis that…
Approved WMOCompleted
To evaluate in a feasibility study whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.